{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T00:27:23Z","timestamp":1721780843295},"reference-count":22,"publisher":"Sociedade Brasileira de Pneumologia e Tisiologia","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Bras Pneumol."],"abstract":"<jats:p>Objective: Cystic fibrosis (CF) affects multiple organs, the most severe consequences being observed in the lungs. Despite significant progress in developing CF transmembrane conductance regulator-specific treatments for CF lung disease, exploring alternative CF-targeted medications seems reasonable. We sought to evaluate the potential beneficial effects of oral benzbromarone as an adjuvant therapy in CF patients with reduced lung function. Methods: This was a prospective open-label pilot study of oral benzbromarone (100 mg\/day) administered once daily for 90 days. Patients were followed at a tertiary referral center in southern Brazil. Safety was assessed by the number of reported adverse events. Secondary objectives included percent predicted FEV1 (FEV1%) and pulmonary exacerbations. Results: Ten patients were enrolled. Benzbromarone was found to be safe, with no serious drug-related adverse events. Eight patients completed the study; the median relative change in FEV1% tended to increase during the treatment, showing an 8% increase from baseline at the final visit. However, a nonparametric test showed that the change was not significant (p = 0.06). Of a total of ten patients, only one experienced at least one pulmonary exacerbation during the study. Conclusions: Oral benzbromarone appears to be safe, and improved FEV1% has been observed in patients with CF. Further assessment in larger trials is warranted to elucidate whether oral benzbromarone can be a potential adjuvant therapy for CF.<\/jats:p>","DOI":"10.36416\/1806-3756\/e20230292","type":"journal-article","created":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T22:46:03Z","timestamp":1721774763000},"page":"e20230292","source":"Crossref","is-referenced-by-count":0,"title":["Benzbromarone as adjuvant therapy for cystic fibrosis lung disease: a pilot clinical trial"],"prefix":"10.36416","author":[{"given":"Frederico","family":"Friedrich1","sequence":"first","affiliation":[{"name":"1. Escola de Medicina, Pontif\u00edcia Universidade Cat\u00f3lica do Rio Grande do Sul \u2013 PUCRS \u2013 Porto Alegre (RS) Brasil."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucas","family":"Montiel Petry1","sequence":"additional","affiliation":[{"name":"1. Escola de Medicina, Pontif\u00edcia Universidade Cat\u00f3lica do Rio Grande do Sul \u2013 PUCRS \u2013 Porto Alegre (RS) Brasil."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"de Castro e Garcia1","sequence":"additional","affiliation":[{"name":"1. Escola de Medicina, Pontif\u00edcia Universidade Cat\u00f3lica do Rio Grande do Sul \u2013 PUCRS \u2013 Porto Alegre (RS) Brasil."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Puerari Pieta1","sequence":"additional","affiliation":[{"name":"1. Escola de Medicina, Pontif\u00edcia Universidade Cat\u00f3lica do Rio Grande do Sul \u2013 PUCRS \u2013 Porto Alegre (RS) Brasil."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda","family":"da Silva Meneses1","sequence":"additional","affiliation":[{"name":"1. Escola de Medicina, Pontif\u00edcia Universidade Cat\u00f3lica do Rio Grande do Sul \u2013 PUCRS \u2013 Porto Alegre (RS) Brasil."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luana","family":"Braga Bittencourt1","sequence":"additional","affiliation":[{"name":"1. Escola de Medicina, Pontif\u00edcia Universidade Cat\u00f3lica do Rio Grande do Sul \u2013 PUCRS \u2013 Porto Alegre (RS) Brasil."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luiza","family":"Fernandes Xavier1","sequence":"additional","affiliation":[{"name":"1. Escola de Medicina, Pontif\u00edcia Universidade Cat\u00f3lica do Rio Grande do Sul \u2013 PUCRS \u2013 Porto Alegre (RS) Brasil."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcos","family":"Ot\u00e1vio Brum Antunes1","sequence":"additional","affiliation":[{"name":"1. Escola de Medicina, Pontif\u00edcia Universidade Cat\u00f3lica do Rio Grande do Sul \u2013 PUCRS \u2013 Porto Alegre (RS) Brasil."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucas","family":"Kich Grun1,2","sequence":"additional","affiliation":[{"name":"1. Escola de Medicina, Pontif\u00edcia Universidade Cat\u00f3lica do Rio Grande do Sul \u2013 PUCRS \u2013 Porto Alegre (RS) Brasil. 2. Laborat\u00f3rio de Imunobiologia, Pontif\u00edcia Universidade Cat\u00f3lica do Rio Grande do Sul \u2013 PUCRS \u2013 Porto Alegre (RS) Brasil."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magali","family":"Lumertz1","sequence":"additional","affiliation":[{"name":"1. Escola de Medicina, Pontif\u00edcia Universidade Cat\u00f3lica do Rio Grande do Sul \u2013 PUCRS \u2013 Porto Alegre (RS) Brasil."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karl","family":"Kunzelmann3","sequence":"additional","affiliation":[{"name":"3. Physiological Institute, University of Regensburg, Regensburg, Germany."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonardo","family":"Araujo Pinto1","sequence":"additional","affiliation":[{"name":"1. Escola de Medicina, Pontif\u00edcia Universidade Cat\u00f3lica do Rio Grande do Sul \u2013 PUCRS \u2013 Porto Alegre (RS) Brasil."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"22288","published-online":{"date-parts":[[2024,7,23]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"1.            Elborn JS. Cystic fibrosis. Lancet. 2016;388(10059):2519-2531. https:\/\/doi.org\/10.1016\/S0140-6736(16)00576-6","DOI":"10.1016\/s0140-6736(16)00576-6"},{"key":"ref1","doi-asserted-by":"crossref","unstructured":"2.            Sanders DB, Fink AK. Background and Epidemiology. Pediatr Clin North Am. 2016;63(4):567-584. https:\/\/doi.org\/10.1016\/j.pcl.2016.04.001","DOI":"10.1016\/j.pcl.2016.04.001"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"3.            Scotet V, L\u2019Hostis C, F\u00e9rec C. The Changing Epidemiology of Cystic Fibrosis: Incidence, Survival and Impact of the CFTR Gene Discovery. Genes (Basel). 2020;11(6):589. https:\/\/doi.org\/10.3390\/genes11060589","DOI":"10.3390\/genes11060589"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"4.            Raskin S, Pereira-Ferrari L, Reis FC, Abreu F, Marostica P, Rozov T, et al. Incidence of cystic fibrosis in five different states of Brazil as determined by screening of p.F508del, mutation at the CFTR gene in newborns and patients. J Cyst Fibros. 2008;7(1):15-22. https:\/\/doi.org\/10.1016\/j.jcf.2007.03.006","DOI":"10.1016\/j.jcf.2007.03.006"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"5.            Sondo E, Caci E, Galietta LJ. The TMEM16A chloride channel as an alternative therapeutic target in cystic fibrosis. Int J Biochem Cell Biol. 2014;52:73-76. https:\/\/doi.org\/10.1016\/j.biocel.2014.03.022","DOI":"10.1016\/j.biocel.2014.03.022"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"6.            Benedetto R, Ousingsawat J, Cabrita I, Pinto M, L\u00e9rias JR, Wanitchakool P, et al. Plasma membrane-localized TMEM16 proteins are indispensable for expression of CFTR. J Mol Med (Berl). 2019;97(5):711-722. https:\/\/doi.org\/10.1007\/s00109-019-01770-4","DOI":"10.1007\/s00109-019-01770-4"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"7.            Benedetto R, Ousingsawat J, Wanitchakool P, Zhang Y, Holtzman MJ, Amaral M, et al. Epithelial Chloride Transport by CFTR Requires TMEM16A. Sci Rep. 2017;7(1):12397. https:\/\/doi.org\/10.1038\/s41598-017-10910-0","DOI":"10.1038\/s41598-017-10910-0"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"8.            Centeio R, Cabrita I, Benedetto R, Talbi K, Ousingsawat J, Schreiber R, et al. Pharmacological Inhibition and Activation of the Ca2+ Activated Cl- Channel TMEM16A. Int J Mol Sci. 2020;21(7):2557. https:\/\/doi.org\/10.3390\/ijms21072557","DOI":"10.3390\/ijms21072557"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"9.            Yang YD, Cho H, Koo JY, Tak MH, Cho Y, Shim WS, et al. TMEM16A confers receptor-activated calcium-dependent chloride conductance. Nature. 2008;455(7217):1210-1215. https:\/\/doi.org\/10.1038\/nature07313","DOI":"10.1038\/nature07313"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"10.          Huang F, Zhang H, Wu M, Yang H, Kudo M, Peters CJ, et al. Calcium-activated chloride channel TMEM16A modulates mucin secretion and airway smooth muscle contraction. Proc Natl Acad Sci U S A. 2012;109(40):16354-16359. https:\/\/doi.org\/10.1073\/pnas.1214596109","DOI":"10.1073\/pnas.1214596109"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"11.          Kunzelmann K, Ousingsawat J, Cabrita I, Dou\u0161ov\u00e1 T, B\u00e4hr A, Janda M, et al. TMEM16A in Cystic Fibrosis: Activating or Inhibiting?. Front Pharmacol. 2019;10:3. https:\/\/doi.org\/10.3389\/fphar.2019.00003","DOI":"10.3389\/fphar.2019.00003"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"12.          Cabrita I, Benedetto R, Schreiber R, Kunzelmann K. Niclosamide repurposed for the treatment of inflammatory airway disease. JCI Insight. 2019;4(15):e128414. https:\/\/doi.org\/10.1172\/jci.insight.128414","DOI":"10.1172\/jci.insight.128414"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"13.          Azevedo VF, Kos IA, Vargas-Santos AB, da Rocha Castelar Pinheiro G, Dos Santos Paiva E. Benzbromarone in the treatment of gout. Adv Rheumatol. 2019;59(1):37. https:\/\/doi.org\/10.1186\/s42358-019-0080-x","DOI":"10.1186\/s42358-019-0080-x"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"14.          Lee MH, Graham GG, Williams KM, Day RO. A benefit-risk assessment of benzbromarone in the treatment of gout. Was its withdrawal from the market in the best interest of patients?. Drug Saf. 2008;31(8):643-665. https:\/\/doi.org\/10.2165\/00002018-200831080-00002","DOI":"10.2165\/00002018-200831080-00002"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"15.          Heel RC, Brogden RN, Speight TM, Avery GS. Benzbromarone: a review of its pharmacological properties and therapeutic use in gout and hyperuricaemia. Drugs. 1977;14(5):349-366. https:\/\/doi.org\/10.2165\/00003495-197714050-00002","DOI":"10.2165\/00003495-197714050-00002"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"16.          Graham BL, Steenbruggen I, Miller MR, Barjaktarevic IZ, Cooper BG, Hall GL, et al. Standardization of Spirometry 2019 Update. An Official American Thoracic Society and European Respiratory Society Technical Statement. Am J Respir Crit Care Med. 2019;200(8):e70-e88. https:\/\/doi.org\/10.1164\/rccm.201908-1590ST","DOI":"10.1164\/rccm.201908-1590st"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"17.          Pereira CA, Sato T, Rodrigues SC. New reference values for forced spirometry in white adults in Brazil. J Bras Pneumol. 2007;33(4):397-406. https:\/\/doi.org\/10.1590\/S1806-37132007000400008","DOI":"10.1590\/S1806-37132007000400008"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"18.          Mall MA, Danahay H, Boucher RC. Emerging Concepts and Therapies for Mucoobstructive Lung Disease. Ann Am Thorac Soc. 2018;15(Suppl 3):S216-S226. https:\/\/doi.org\/10.1513\/AnnalsATS.201806-368AW","DOI":"10.1513\/annalsats.201806-368aw"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"19.          Danahay HL, Lilley S, Fox R, Charlton H, Sabater J, Button B, et al. TMEM16A Potentiation: A Novel Therapeutic Approach for the Treatment of Cystic Fibrosis. Am J Respir Crit Care Med. 2020;201(8):946-954. https:\/\/doi.org\/10.1164\/rccm.201908-1641OC","DOI":"10.1164\/rccm.201908-1641oc"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"20.          Miner K, Labitzke K, Liu B, Wang P, Henckels K, Gaida K, et al. Drug Repurposing: The Anthelmintics Niclosamide and Nitazoxanide Are Potent TMEM16A Antagonists That Fully Bronchodilate Airways. Front Pharmacol. 2019;10:51. https:\/\/doi.org\/10.3389\/fphar.2019.00051","DOI":"10.3389\/fphar.2019.00051"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"21.          Gallos G, Remy KE, Danielsson J, Funayama H, Fu XW, Chang HY, et al. Functional expression of the TMEM16 family of calcium-activated chloride channels in airway smooth muscle. Am J Physiol Lung Cell Mol Physiol. 2013;305(9):L625-L634. https:\/\/doi.org\/10.1152\/ajplung.00068.2013","DOI":"10.1152\/ajplung.00068.2013"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"22.          Huang F, Rock JR, Harfe BD, Cheng T, Huang X, Jan YN, et al. Studies on expression and function of the TMEM16A calcium-activated chloride channel. Proc Natl Acad Sci U S A. 2009;106(50):21413-21418. https:\/\/doi.org\/10.1073\/pnas.0911935106","DOI":"10.1073\/pnas.0911935106"}],"container-title":["Jornal Brasileiro de Pneumologia"],"original-title":[],"language":"en","deposited":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T22:46:26Z","timestamp":1721774786000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jornaldepneumologia.com.br\/details\/3964\/en-US"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,23]]},"references-count":22,"URL":"https:\/\/doi.org\/10.36416\/1806-3756\/e20230292","relation":{},"ISSN":["1806-3756"],"issn-type":[{"value":"1806-3756","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,23]]}}}